Highmark Covering Rosetta Genomics' Cancer MDx | GenomeWeb

NEW YORK (GenomeWeb News) – Rosetta Genomics announced today that its Rosetta Cancer Origin Test has received in-network provider status with Highmark Health Services.

Highmark Health is a subsidiary of Highmark and the fourth-largest Blue Cross Blue Shield-affiliated company, providing coverage for 5.3 million people in Pennsylvania, Delaware, and West Virginia. Its members now have access to Rosetta's test for identifying the tumor origin in cancer of unknown or uncertain primary as an in-network service.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.